WILMINGTON, Delaware (Reuters) -Pfizer ( PFE ) has removed some conditions in its bid for Metsera ( MTSR ) as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Delaware judge on Wednesday.

Pfizer ( PFE ) will ask a Delaware judge at a hearing on Wednesday to prevent Metsera ( MTSR ) from ending their merger agreement in favor of Novo's offer. Pfizer ( PFE ) said it removed conditions on direct sales of stock and public statements by Metsera ( MTSR ).